Drugs / GEN1042
GEN1042
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06057038 | Nov 2023 → Aug 2027 expected | cancer | Genmab | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05491317 | Mar 2023 → Aug 2025 | — | Genmab | Terminated | No outcome recorded |
| Phase 1/2 | NCT04083599 | Sep 2019 → Dec 2025 overdue | colorectal carcinoma, head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma +1 | Genmab | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEN1042 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05491317 ↗ |
| Known as | BNT312 | “DuoBody-CD40×4-1BB (GEN1042/BNT312) is a novel investigational Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB to enhance priming...” PMID 35688554 ↗ Jun 2022 |
| Known as | DuoBody-CD40×4-1BB | “DuoBody-CD40×4-1BB (GEN1042/BNT312) is a novel investigational Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB to enhance priming...” PMID 35688554 ↗ Jun 2022 |
| Known as | GEN1042 (DuoBody-CD40x4-1BB) | “GEN1042 (DuoBody®-CD40x4-1BB)” NCT06057038 ↗ |
| Action | Activate | “DuoBody-CD40×4-1BB exhibited conditional CD40 and 4-1BB agonist activity that was strictly dependent on crosslinking of both targets.” PMID 35688554 ↗ Jun 2022 |
| Route | Intravenous | “Intravenous” NCT05491317 ↗ |